扩张型心肌病轻中度左室收缩功能不全患者壁中晚期钆增强与心脏性猝死的关联
该前瞻性研究纳入399例扩张型心肌病且左室射血分数(LVEF)≥40%的患者,中位随访4.6年,评估壁中晚期钆增强(LGE)与心脏性猝死(SCD)或中止的SCD的关联。结果显示LGE阳性患者复合终点风险显著高于LGE阴性患者(HR 9.2,95%CI 3.9-21.8,P<0.0001),提示壁中LGE可识别SCD高风险且非猝死风险低的患者,可能从植入式心律转复除颤器植入中获益。
要点
- 在LVEF≥40%的扩张型心肌病患者中,壁中LGE阳性者SCD或中止的SCD风险显著高于LGE阴性者(HR 9.2)。
- LGE阳性患者心脏性猝死风险(HR 4.9)及中止的SCD风险(HR 34.8)均显著高于LGE阴性者。
- 壁中LGE可识别SCD风险高而非猝死风险低的患者,可能从ICD植入中获益。
核心结论
- 壁中LGE可识别一组LVEF≥40%的扩张型心肌病患者,其SCD风险增加而非猝死风险低,可能从植入式心律转复除颤器植入中获益。
研究设计与样本
- 前瞻性研究,纳入2000年1月至2011年12月间连续转诊至该中心的扩张型心肌病且LVEF≥40%、无植入式心律转复除颤器植入指征的患者,共399例(145例女性,中位年龄50岁,中位LVEF 50%,25.3%有LGE),中位随访4.6年。
主要发现
- LGE阳性组101例中18例(17.8%)达到预设复合终点,LGE阴性组298例中7例(2.3%)达到,HR 9.2(95%CI 3.9-21.8,P<0.0001)。
- LGE阳性组9例(8.9%)发生心脏性猝死,LGE阴性组6例(2.0%)发生,HR 4.9(95%CI 1.8-13.5,P=0.002)。
- LGE阳性组10例(9.9%)发生中止的SCD,LGE阴性组1例(0.3%)发生,HR 34.8(95%CI 4.6-266.6,P<0.001)。
- 校正后LGE仍预测复合终点(HR 9.3,95%CI 3.9-22.3,P<0.0001)、SCD(HR 4.8,95%CI 1.7-13.8,P=0.003)及中止的SCD(HR 35.9,95%CI 4.8-271.4,P<0.001)。
- 与无LGE者相比,LGE范围0%-2.5%、2.5%-5%及>5%的患者复合终点估计HR分别为10.6(95%CI 3.9-29.4)、4.9(95%CI 1.3-18.9)和11.8(95%CI 4.3-32.3)。
临床怎么用
- 原文结论指出,壁中LGE识别的LVEF≥40%扩张型心肌病患者可能从植入式心律转复除颤器植入中获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current guidelines only recommend the use of an implantable cardioverter defibrillator in patients with dilated cardiomyopathy for the primary prevention of sudden cardiac death (SCD) in those with a left ventricular ejection fraction (LVEF) <35%. However, registries of out-of-hospital cardiac arrests demonstrate that 70% to 80% of such patients have an LVEF >35%. Patients with an LVEF >35% also have low competing risks of death from nonsudden causes. Therefore, those at high risk of SCD may gain longevity from successful implantable cardioverter defibrillator therapy. We investigated whether late gadolinium enhancement (LGE) cardiovascular magnetic resonance identified patients with dilated cardiomyopathy without severe LV systolic dysfunction at high risk of SCD. METHODS: We prospectively investigated the association between midwall LGE and the prespecified primary composite outcome of SCD or aborted SCD among consecutive referrals with dilated cardiomyopathy and an LVEF ≥40% to our center between January 2000 and December 2011 who did not have a preexisting indication for implantable cardioverter defibrillator implantation. RESULTS: Of 399 patients (145 women, median age 50 years, median LVEF 50%, 25.3% with LGE) followed for a median of 4.6 years, 18 of 101 (17.8%) patients with LGE reached the prespecified end point, compared with 7 of 298 (2.3%) without (hazard ratio [HR], 9.2; 95% confidence interval [CI], 3.9-21.8; P<0.0001). Nine patients (8.9%) with LGE compared with 6 (2.0%) without (HR, 4.9; 95% CI, 1.8-13.5; P=0.002) died suddenly, whereas 10 patients (9.9%) with LGE compared with 1 patient (0.3%) without (HR, 34.8; 95% CI, 4.6-266.6; P<0.001) had aborted SCD. After adjustment, LGE predicted the composite end point (HR, 9.3; 95% CI, 3.9-22.3; P<0.0001), SCD (HR, 4.8; 95% CI, 1.7-13.8; P=0.003), and aborted SCD (HR, 35.9; 95% CI, 4.8-271.4; P<0.001). Estimated HRs for the primary end point for patients with an LGE extent of 0% to 2.5%, 2.5% to 5%, and >5% compared with those without LGE were 10.6 (95% CI, 3.9-29.4), 4.9 (95% CI, 1.3-18.9), and 11.8 (95% CI, 4.3-32.3), respectively. CONCLUSIONS: Midwall LGE identifies a group of patients with dilated cardiomyopathy and an LVEF ≥40% at increased risk of SCD and low risk of nonsudden death who may benefit from implantable cardioverter defibrillator implantation. CLINICAL TRIAL REGISTRATION: URL: http://clinicaltrials.gov. Unique identifier: NCT00930735.
引用
- Halliday BP, Gulati A, Ali A, et al. Association Between Midwall Late Gadolinium Enhancement and Sudden Cardiac Death in Patients With Dilated Cardiomyopathy and Mild and Moderate Left Ventricular Systolic Dysfunction. Circulation. 2017. PMID: 28351901. doi:10.1161/CIRCULATIONAHA.116.026910
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。